SCHEMBL1109024

SCHEMBL1109024

COc1ccc(CN(c2ncc(Cl)s2)S(=O)(=O)c2cc(C)c(F)cc2F)c(OC)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
OXTR P30559 2/20 0.36
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
ALDH1A1 P00352 3/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TSHR P16473 4/20 0.33
CYP1A2 P05177 3/20 0.33
CYP3A4 P08684 3/20 0.33
CYP2D6 P10635 3/20 0.33
CYP2C19 P33261 3/20 0.33
HSD17B10 Q99714 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
ALOX15 P16050 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1094098 0.94 KDM4E (0.37) CNR1CNR2MEN1KMT2AOXTR
SCHEMBL1093971 0.92 KDM4E (0.36) CNR1CNR2MEN1KMT2AOXTR
SCHEMBL18983167 0.91 CNR1 (0.38) CNR1CNR2MEN1KMT2AOXTR
SCHEMBL16757127 0.88 SLC22A12 (0.36) CNR1CNR2KDM4ETP53GAA
SCHEMBL18352659 0.87 CNR1 (0.37) CNR1CNR2MEN1KMT2AOXTR
SCHEMBL33372518 0.86 KDM4E (0.37) CNR1CNR2MEN1KMT2AOXTR
SCHEMBL16757059 0.85 CNR1 (0.44) CNR1CNR2MEN1KMT2AOXTR
SCHEMBL13452404 0.85 MEN1 (0.41) MEN1KMT2AKDM4EGAAALDH1A1
SCHEMBL14921462 0.85 CNR1 (0.47) CNR1CNR2MEN1KMT2AOXTR
SCHEMBL16757426 0.84 KDM4E (0.36) CNR1CNR2MEN1KMT2AOXTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 CNR1 913/4885CNR2 290/4885MEN1 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.